About: 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually. We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%. Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics. Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low. Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide. High risk myelomas should be treated individually. (en)
Title	10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group (en)
skos:prefLabel	10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group 10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group (en)
skos:notation	RIV/00064173:_____/13:#0000375!RIV14-MZ0-00064173
http://linked.open...avai/predkladatel	Fakultní nemocnice Královské Vinohrady
http://linked.open...avai/riv/aktivita	P V Z
http://linked.open...avai/riv/aktivity	P(NT12215), P(NT14393), V, Z(MSM0021622434)
http://linked.open...iv/cisloPeriodika	9
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Gregora, Evžen
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice Královské Vinohrady
http://linked.open...dnocenehoVysledku	119603
http://linked.open...ai/riv/idVysledku	RIV/00064173:_____/13:#0000375
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Multiple myeloma; Thalidomide (en)
http://linked.open.../riv/klicoveSlovo	Multiple myeloma Thalidomide
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[847083980703]
http://linked.open...i/riv/nazevZdroje	Leukemia Research
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	22 (xsd:int)
http://linked.open...vavai/riv/projekt	Signalling pathways in myeloma bone disease Rationalization of therapy of multiple myeloma
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	37
http://linked.open...iv/tvurceVysledku	Gregora, Evžen
http://linked.open...ain/vavai/riv/wos	000324097600014
http://linked.open...n/vavai/riv/zamer	From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
issn	0145-2126
number of pages	7 (xsd:int)
http://bibframe.org/vocab/doi	10.1016/j.leukres.2013.06.019

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software